A Minimalist Binary Vaccine Carrier for Personalized Postoperative Cancer Vaccine Therapy

A Minimalist Binary Vaccine Carrier for Personalized Postoperative Cancer Vaccine Therapy

© 2022 Wiley-VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 34(2022), 10 vom: 07. März, Seite e2109254
1. Verfasser: Zhao, Jiayu (VerfasserIn)
Weitere Verfasser: Xu, Yudi, Ma, Sheng, Wang, Yibo, Huang, Zichao, Qu, Haoyuan, Yao, Haochen, Zhang, Yu, Wu, Guanglu, Huang, Leaf, Song, Wantong, Tang, Zhaohui, Chen, Xuesi
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article cancer immunotherapy cancer vaccine nanovaccine polymeric carriers postoperative therapy Cancer Vaccines
Beschreibung
Zusammenfassung:© 2022 Wiley-VCH GmbH.
In recent years, significant evolutions have been made in applying nanotechnologies for prophylactic and therapeutic cancer vaccine design. However, the clinical translation of nanovaccines is still limited owing to their complicated compositions and difficulties in the spatiotemporal coordination of antigen-presenting cell activation and antigen cross-presentation. Herein, a minimalist binary nanovaccine (BiVax) is designed that integrates innate stimulating activity into the carrier to elicit robust antitumor immunity. The authors started by making a series of azole molecules end-capped polyethylenimine (PEI-M), and were surprised to find that over 60% of the PEI-M polymers have innate stimulating activity via activation of the stimulator of interferon genes pathway. PEI-4BImi, a PEI-M obtained from a series of polymers, elicits robust antitumor immune responses when used as a subcutaneously injected nanovaccine by simply mixing with ovalbumin antigens, and this BiVax system performs much better than the traditional ternary vaccine system, as well as, commercialized aluminum-containing adjuvants. This system also enables the fast preparation of personalized BiVax by compositing PEI-4BImi with autologous tumor cell membrane protein antigens, and a 60% postoperative cure rate is observed when combined with immune checkpoint inhibitors
Beschreibung:Date Completed 31.03.2022
Date Revised 01.04.2022
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-4095
DOI:10.1002/adma.202109254